Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...